Health
Specific amount of nightly sleep may lower diabetes risk, researchers find
NEWYou can now listen to Fox News articles!
Getting a certain amount of sleep could help ward off diabetes, a new study suggests.
A team of Chinese researchers studied how sleep duration on weekdays is associated with insulin resistance, a key risk factor for type 2 diabetes. The long-term observational study, held from 2009 to 2023, included about 25,000 participants.
The “sweet spot” for low insulin resistance was about seven hours and 18 minutes of sleep per night, found the research, which was published in BMJ Open Diabetes Research & Care.
ANCIENT HERB KNOWN AS ‘NATURE’S VALIUM’ TOUTED FOR IMPROVING SLEEP AND ANXIETY
Large deviations from this benchmark — either too much or too little sleep — were associated with worse insulin sensitivity. Shorter sleep was linked with higher insulin resistance, while longer sleep had worse metabolic markers.
Getting extra “catch-up” sleep on the weekends did not make up for deficits during the week, the study found, as excessive sleep showed a risk of worsening glucose metabolism in some participants.
A new study suggests that getting just over seven hours of sleep per night could prevent diabetes. (iStock)
“These correlational findings suggest that sleep patterns, particularly weekend recovery sleep, may be relevant for metabolic regulation in diabetes and could inform considerations for healthcare professionals in managing patient care,” the researchers concluded in the study.
As this was an observational study, the findings show associations rather than cause and effect, they noted. Sleep duration was also self-reported, which could pose a limitation.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The study did not measure sleep quality, which could play a role in outcomes. Other lifestyle factors, like diet, stress and shift work, could influence results as well.
Fox News Digital reached out to the study authors for comment.
‘Useful’ yet ‘too simplistic’
Fox News senior medical analyst Dr. Marc Siegel said the study produced “useful information.”
“We have long known that there is an association between sleep and insulin resistance,” Siegel, who was not involved in the research, told Fox News Digital. “This is because the restorative aspect of sleep helps to regulate metabolic function and hormones, and also decrease inflammation.”
More than 40 million Americans — about 12% of the population — have diabetes, according to 2026 CDC data. (iStock)
“But as this study shows, both too much and too little sleep may lead to more insulin resistance (and diabetes) via metabolic dysregulation,” he added.
Dr. Aaron Pinkhasov, a board-certified psychiatrist and chair of the department of psychiatry at NYU Grossman Long Island School of Medicine, said the concept of sleeping a certain number of hours to prevent diabetes is “too simplistic.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Sleep is only one part of metabolic health, along with genetics, body weight, diet, physical activity and stress,” the sleep expert, who also wasn’t part of the study, told Fox News Digital.
“Sleep is only one part of metabolic health, along with genetics, body weight, diet, physical activity and stress,” an expert said. (iStock)
“The study provides only a snapshot in time, so it cannot prove that sleep duration actually causes insulin resistance,” he went on. “It is also possible that underlying problems — such as metabolic illness, pain, depression or low activity — lead people to sleep longer or shorter.”
CLICK HERE FOR MORE HEALTH STORIES
The “practical message” for adults, according to Pinkhasov, is to aim for about seven to nine hours of quality sleep on a regular schedule, as part of an “overall strategy to reduce diabetes risk.”
“The study strengthens the idea that sleep should be considered as important as diet and exercise when discussing diabetes risk,” he added. “The key message is not the exact number of hours, but that both chronic sleep deprivation and irregular sleep patterns are associated with higher insulin resistance.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
More than 40 million Americans — about 12% of the population — have diabetes, according to 2026 CDC data. About 11 million (27.6%) of cases are undiagnosed, and more than 115 million U.S. adults have prediabetes.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
Pancreatic cancer patient Ben Sasse sees ‘massive’ tumor reduction with experimental new drug
NEWYou can now listen to Fox News articles!
Months after revealing his stage 4 cancer diagnosis, former U.S. Sen. Ben Sasse is speaking out about an experimental therapy that could extend his life.
Sasse, a Republican who represented Nebraska between 2015 and 2023, shared in December 2025 that he has metastatic pancreatic cancer, which has spread to multiple organs — including his liver and lungs.
After initially being given three to four months to live, Sasse, 54, entered a clinical trial for a drug called daraxonrasib, an oral therapy (pill) that is designed to block the defective gene that triggers uncontrolled cellular growth.
CANCER SURVIVAL APPEARS TO DOUBLE WITH COMMON VACCINE, RESEARCHERS SAY
The California-based drugmaker, Revolution Medicines, recently shared data from a phase 3 clinical trial of people with metastatic pancreatic cancer who did not respond to standard chemotherapy.
Patients on the treatment lived a median of 13 months, compared to around six months for those who continued with chemo.
Former Sen. Ben Sasse of Nebraska entered a clinical trial for a drug called daraxonrasib, an oral therapy (pill) that is designed to block the defective gene that triggers uncontrolled cellular growth. (Anna Moneymaker/Getty Images)
“I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months,” Sasse told “60 Minutes” in a recent interview.
Daraxonrasib works by going after a key growth “switch” in many cancers called RAS, according to Sarbajit Mukherjee, M.D., chief of gastrointestinal medical oncology at Miami Cancer Institute, part of Baptist Health South Florida.
MAN WITH STAGE 4 CANCER RAISES $150K FOR EXPERIMENTAL TREATMENT
“In pancreatic cancer, that switch is stuck in the ‘on’ position in the vast majority of tumors, constantly telling the cancer cells to grow and spread,” the doctor, who was not involved in the trial and did not treat Sasse, told Fox News Digital.
“Daraxonrasib is designed to bind to RAS in its active state and turn down that signal, which can slow or shrink the cancer.”
“The drug is in the final stages of clinical trials, where it has been shown to double the survival of those previously treated for metastatic pancreatic cancer.”
Pancreatic cancer is difficult to diagnose early because there are generally no symptoms — or only subtle gastrointestinal symptoms — until it is already widespread, according to Dr. Marc Siegel, Fox News senior medical analyst.
“This is the first-of-its-kind targeted therapy for pancreatic cancer,” Siegel, who also was not involved in the research or the senator’s treatment, told Fox News Digital. “The drug is in the final stages of clinical trials, where it has been shown to double the survival of those previously treated for metastatic pancreatic cancer.”
Sasse, shown above, announced his diagnosis late last year. An expert noted that the survival boost seen from the clinical trial is a “big difference” for a disease that typically has much shorter survival times. (Win McNamee/Getty Images)
Mukherjee noted that the survival boost seen in the trial is a “big difference” for a disease that typically has much shorter survival times.
“From my perspective, as someone who treats pancreatic cancer every day, daraxonrasib is the first targeted pill in this disease that truly feels like a step change rather than a small incremental improvement,” he said.
“It opens the door to much more personalized strategies going forward. For a cancer where progress has been painfully slow, it could reshape how we care for patients with advanced disease.”
RECTAL CANCER DEATHS RISING UP TO THREE TIMES FASTER IN SPECIFIC AGE GROUP, STUDY FINDS
While current chemotherapy options can shrink pancreatic tumors and help people live longer, they are “tough,” Mukherjee noted — “and once they stop working, our options are limited and survival is usually measured in just a few more months.”
Early data also suggest that when daraxonrasib is combined with standard chemotherapy as the first treatment, there is more shrinkage of tumors and more patients doing well at six months than they typically would only with chemotherapy.
Sasse shared in December 2025 that he has metastatic pancreatic cancer, which has spread to multiple organs, including his liver and lungs. (Meghan McCarthy/Palm Beach Daily News/USA TODAY NETWORK via Imagn Images)
If the drug is approved, it will likely become an important option for patients when standard chemotherapy stops working, Mukherjee suggested.
“Ongoing trials are now asking whether it should also be used as part of the very first treatment plan,” he added.
NEW CANCER VACCINE SHOWS PROMISING RESULTS FOR CERTAIN PATIENTS
Although the drug is described as “well-tolerated” compared to chemotherapy, the doctor noted that, like any strong cancer drug, daraxonrasib has side effects.
“The ones we see most often include rash, diarrhea, mouth sores and fatigue, with patients needing regular blood tests and close follow‑up while on treatment,” Mukherjee said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
In the clinical trials, most of these problems have been managed by adjusting the dose or adding supportive medications.
“The limitations are important to be transparent about — it is still not yet FDA‑approved, and it is not a cure,” Mukherjee noted.
In addition to the daraxonrasi, Sasse credits his faith for helping him beat his original prognosis. (Drew Angerer/Getty Images)
“Over time, most cancers will eventually find ways to grow around the drug.”
CLICK HERE FOR MORE HEALTH STORIES
In addition to daraxonrasib, which he calls a “miracle” drug, Sasse credits his faith for helping him beat his original prognosis.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“It’s weird to be in your early 50s and get a terminal diagnosis, and people all of a sudden act like you’re 93 or 94, and you have a lot of wisdom,” he said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“I don’t know that I have a lot of wisdom, but I have a lot of things that I think we should be reflecting on together.”
Fox News Digital reached out to Sasse for further comment, and to the head of the clinical trial as well.
The Supreme Court appeared divided on Monday during arguments in a dispute that could determine the fate of thousands of lawsuits that claim a widely used weedkiller causes cancer.
The case is the latest turn in a yearslong legal battle over safety concerns with the weedkiller Roundup. Developed by Monsanto in the 1970s, the herbicide is the focus of the lawsuits, which allege that it causes non-Hodgkin lymphoma.
The dispute before the justices stems from a 2019 lawsuit brought by a Missouri gardener, John Durnell, who used Roundup for years. Mr. Durnell claimed in his suit, filed in state court, that glyphosate, a chemical in the weedkiller, caused him to develop cancer.
During Monday’s oral argument, several of the justices expressed skepticism of arguments by Bayer, the German conglomerate that acquired Monsanto in 2018, and the Trump administration, which joined the case in support of the company, that federal rules requiring herbicide safety labeling should bar people from filing state-level claims that accuse companies of failing to warn consumers of dangers.
Chief Justice John G. Roberts Jr. asked a lawyer for the Trump administration whether states would be blocked from taking action if new scientific information raised alarms about a product.
“The states cannot do anything?” the chief justice asked.
Sarah M. Harris, a principal deputy solicitor general, responded that it would be problematic to have each state “jumping the gun” to come to its own conclusion about whether a product caused cancer.
Mr. Durnell’s lawyer argued that the federal Environmental Protection Agency had overreached its regulatory power, a problem that could be rectified by giving a role to the courts, including at the state level. Several of the justices appeared skeptical about that argument too, questioning whether such a ruling would lead to a patchwork of safety regulations throughout the country.
In 2023, a Missouri jury awarded Mr. Durnell $1.25 million in damages. If the court finds for the company, that verdict would be erased and other claims against the company also endangered. If the court finds for Mr. Durnell, not only would his verdict be upheld but it would also clear the way for a flood of other lawsuits to proceed in courts throughout the country.
A ruling is expected by the end of June or early July.
The central issue in the case involves a collision between state and federal power. Bayer has argued that Mr. Durnell’s victory in Missouri is barred by a federal law, the Federal Insecticide, Fungicide and Rodenticide Act. That statute requires herbicides to be registered with the E.P.A. before they can be sold. Companies must submit scientific and safety data to the agency, along with proposed label information, including safety warnings.
The E.P.A. has previously determined that Roundup is safe to use. Bayer argued that the Missouri court ruling conflicted with that federal determination. Paul D. Clement, who represented Bayer, asserted that the federal agency’s decision invalidates the state court decision.
Got a news tip about the courts? If you have information to share about the Supreme Court or other federal courts, please contact us.
Bayer has also said it cannot add warnings to Roundup in any state because they would contradict the E.P.A.’s findings.
In a brief to the justices, lawyers for Bayer wrote that the E.P.A. had “repeatedly determined” that glyphosate does not cause cancer, asserting that the company would not be able to “unilaterally alter the label’s precautionary warnings to include a cancer warning.”
The company appealed the jury verdict in the Missouri case and, after the Missouri Court of Appeals upheld the trial court, asked the justices to weigh in.
Early this year, President Trump issued an executive order that cited the Defense Production Act to guarantee production of glyphosate-based herbicides, appearing to elevate Roundup to a national security priority.
Lawyers for Mr. Durnell argued that nothing in the federal law blocked Bayer from adding a cancer warning to its labels and that such a change would not require E.P.A. approval.
Mr. Durnell was represented by Ashley C. Keller and Jonathan F. Mitchell, a prominent conservative appellate lawyer who represented Mr. Trump in his successful 2024 bid to remain on the Colorado ballot. Both lawyers joined the Supreme Court case only in recent months.
Another lawyer, David C. Frederick, had initially filed briefs on Mr. Durnell’s behalf. In the weeks before the argument, Mr. Frederick asked the justices if he could participate in the argument on behalf of more than 11,500 other people whose claims would be affected by the court’s decision. The justices denied the request.
-
Arizona2 minutes agoArizona prison fight not a riot, though injuries reported
-
Arkansas8 minutes agoBoth sides oppose federal lawsuit over Arkansas election law being found moot | Arkansas Democrat Gazette
-
California14 minutes agoA Santa Barbara Restaurant Vet Introduces Spanish-California Cooking to West Adams
-
Colorado20 minutes agoColorado real estate broker expands to Breckenridge
-
Connecticut26 minutes agoMan convicted almost 4 years after body found in the Connecticut River
-
Delaware32 minutes agoMezzanine Gallery presents Kira Krell’s “Stone Formations”
-
Florida38 minutes agoFBI asking for help locating missing truck driver after suspected car hauler hijacking in Florida
-
Georgia44 minutes ago
Georgia officials warn wildfires are still a threat as firefighters report progress
